Sep 2026· Cancer Medicine· Vol 15· 0 citations· 24 references
Medicine
TL;DR
In conclusion, CAR‐T therapy offers similar efficacy and safety in R/R B‐ALL patients regardless of CNS involvement, and consolidative allo‐HSCT as consolidation post‐CAR‐T as an independent protective factor for improved EFS and OS in CNSL patients.
Abstract
Central nervous system (CNS) involvement in B‐cell acute lymphoblastic leukemia (B‐ALL) is associated with relapse, treatment refractoriness, and poor prognosis. Although chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in relapsed/refractory (R/R) B‐ALL, its efficacy and safety in CNS leukemia (CNSL) remain unclear. We retrospectively analyzed 113 R/R B‐ALL patients who received CAR‐T cell therapy, stratifying them into CNS‐positive (n = 22) and CNS‐negative (n = 91) groups based on the presence of CNSL prior to infusion. At Day 28 after CAR‐T infusion, the overall complete remission (CR) rate was 81.8%, with no significant difference between groups. The incidence of cytokine release syndrome (CRS) and neurotoxicity was comparable. The 3‐year cumulative incidence of relapse (CIR), event‐free survival (EFS), and overall survival (OS) were similar between groups. However, CNSL patients exhibit a higher cumulative relapse rate following CAR‐T‐induced remission, with an increased risk of CNS relapse compared to patients without CNS involvement. Multivariate analysis identified allo‐HSCT as consolidation post‐CAR‐T as an independent protective factor for improved EFS and OS in CNSL patients. In conclusion, CAR‐T therapy offers similar efficacy and safety in R/R B‐ALL patients regardless of CNS involvement. Furthermore, CAR‐T cell therapy was not sufficient to maintain sustained remission, and consolidative allo‐HSCT may improve long‐term survival in this high‐risk group.
Patients with relapsed or refractory primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) have limited treatment options and poor outcomes. CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has shown promising activity in this setting; however, the available e...
Anfal Khan, A. A. Malik, Waqas Kareem et al.· eJHaem· 0 citations
Current evidence remains largely preliminary and is limited by the paucity of randomized prospective trials, although relapse management is disease-specific and increasingly incorporates novel therapeutic agents, including bispecific antibodies (BsAbs) and other targeted therapies.
Martina Canichella, E. Abruzzese, Mariagiovanna Cefalo et al.· Cells· 0 citations
Abstract Background CD19-targeting chimeric antigen receptor T-cells (CAR-T) and blinatumomab represent two leading immunotherapies for relapsed/refractory B cell acute lymphoblastic leukemia (r/r B-ALL). Despite sharing the same target, their differential clinical efficacy and underlying mechanisms remain unclear. Met...
Ke-Xin Wang, Lei Yu, Xing-Hua Liang et al.· Journal for ImmunoTherapy of...· 0 citations
Donor-derived anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) therapy has emerged as one of the most promising treatments for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In this retrospective study, we evaluated the safety and efficacy of donor-derived anti-CD19 CAR T cells manufactur...
Supavich Tannumsaeng, U. Anurathapan, Arpatsorn Sermcheep et al.· Cancer Chemotherapy and Phar...· 0 citations
Background T-cell acute lymphoblastic leukemia (T-ALL) with ABL1 rearrangement is an extremely rare disease, and its clinical significance has not been precisely defined. We report the clinical characteristics of a pediatric patient with T-cell acute lymphoblastic leukemia harboring ABL1 rearrangement and the treatment...
Ming-Yan Zhong, Wen-Ting He, Ling-Ji Zeng et al.· Frontiers in Oncology· 0 citations
It is suggested that lineage plasticity might represent an under-recognized mechanism of resistance to CD7-directed CAR-T therapy in T-ALL/LBL, particularly in ETP-ALL/LBL, warranting further exploring.
Jia-Hua Niu, Kun Wang, Shi-Zhen Qiu et al.· Transplantation and Cellular...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.